Navigation Links
Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
Date:2/27/2008

ence call will be available for replay through March 12, 2008.

To access the conference call, follow these instructions:

Dial: (866) 314-5232 (U.S.); (617) 213-8052 (international)

Passcode: 94561493 (Howard Robin is the host)

Audio replay dial-in and passcode:

Dial: (888) 286-8010 (U.S.) ;(617) 801-6888 (international)

Passcode: 92959414

About Nektar

Nektar Therapeutics is a biopharmaceutical company with a mission to develop and enable differentiated therapeutics with its industry-leading pulmonary and PEGylation technology platforms. Nektar pulmonary and PEGylation technology, expertise, manufacturing capabilities and know-how have enabled ten approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its pulmonary and PEGylation technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.

This press release contains forward-looking statements that reflect the company's current views as to the value of its technology platforms and clinical pipeline of product candidates and overall prospects for the company's business. These forward-looking statements involve risks and uncertainties, including but not limited to: (i) the company's proprietary product candidates and those of certain of its partners are in the early phases of clinical development and the risk of failure is high and can occur at any stage prior to regulatory approval, (ii) the timing or success of the commencement or end of clinical trials is subject to a number of uncertainties including but not limited to patient enrollment, clinical drug manufacturing, regulatory requirements and clinical outcomes, and (iii) the company's or its partner's success in obtaining regulatory approvals for product candidates. Other important risks and uncertainties are det
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
2. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
3. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
4. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
5. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
6. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
7. Prime Therapeutics Receives TIPPS Certification
8. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
9. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
10. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
11. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... News) -- Although cervical cancers are declining in the ... papillomavirus (HPV) are increasing, a new study indicates. ... the tongue and tonsils have increased over the past ... 45, the Canadian researchers report. "The increases in ... and of anal cancer among younger women are disturbing, ...
(Date:7/25/2014)... 2014 The Europe Cyber Security report ... Europe with analysis and forecast of revenue. This market ... 2014 to $19.07 billion by 2019, at a CAGR ... the TOC of the Europe Cyber Security Market report ... It also provides a glimpse of the segmentation in ...
(Date:7/25/2014)... American Brain Tumor Association (ABTA) today unveiled branding of ... patient and family conference in Chicago. , “This is ... we – the first and now only national organization ... tumor research – extend our reach by engaging volunteers ... our materials and services into the hands of those ...
(Date:7/25/2014)... Chicago, IL (PRWEB) July 25, 2014 Today, ... brain tumor, and yet, when it comes to pinpointing causes ... “Right now, we don’t know who, we don’t know when, ... Elizabeth M. Wilson, MNA, president & CEO, American Brain Tumor ... why the American Brain Tumor Association funds research to pursue ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... Substrate Wafer, Devices, Applications, and Geography - Analysis & ... by substrate is expected to reach $3.01 Billion by ... Sapphire Technology Market for devices is expected to reach ... that includes an in-depth analysis of application and geography. ...
Breaking Medicine News(10 mins):Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 2Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 3Health News:Europe Cyber Security Market is Expected to Reach $19 billion in 2019 - New Report by MicroMarket Monitor 4Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 2Health News:American Brain Tumor Association Unveils Brand Identity for Newly Launched Volunteer Network 3Health News:Brain Tumor Causes and Risk Factors Elude Scientists 2Health News:Brain Tumor Causes and Risk Factors Elude Scientists 3Health News:Brain Tumor Causes and Risk Factors Elude Scientists 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Sapphire Technology Market Estimated to Reach $3.01 Billion by 2020 – New Report by MarketsandMarkets 6
... exposure causes genetic changes in breast cells , , THURSDAY, ... many plastic products used in households caused accelerated breast ... a condition that might predispose the animals to breast ... Butyl benzyl phthalate (BBP) is commonly used to soften ...
... occurrence in television shows and movies, but can watching it make ... Although research has shown ... there has been little direct neuroscientific support for this theory until ... Researchers at Columbia University Medical Centers Functional ...
... Program Sets Stage for Increased Visibility ... Among Shareholders and Investors, ... EMIS ) announced today that it has retained Adam,Friedman Associates, ... is a biopharmaceutical company that focuses on a,unique and improved ...
... Insmed Inc. (Nasdaq:,INSM), a developer of follow-on biologics and ... 5th Annual Global Follow-On Biologics,Conference on December 11, 2007 ... be held at the Hyatt Regency Hotel in Reston,Virginia, ... and will bring together corporate, regulatory, financial, and legal,experts ...
... SAN FRANCISCO, Calif., Dec. 6 Proteolix, Inc.,announced ... studies using,intravenous carfilzomib (PR-171) are to be presented ... Meeting in Atlanta, Georgia, December,8-10, 2007. Carfilzomib is ... for the treatment of multiple myeloma,lymphoma and solid ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) announced today details of ... chronic myelogenous leukemia,(CML) at the upcoming American Society of Hematology,s ... 8th - 11th, 2007 in,Atlanta, Georgia., , The schedule ... Date: ...
Cached Medicine News:Health News:Common Household Chemical Could Raise Breast Cancer Risk 2Health News:Common Household Chemical Could Raise Breast Cancer Risk 3Health News:This is your brain on violent media 2Health News:Emisphere Names Adam Friedman Associates IR Agency of Record 2Health News:Emisphere Names Adam Friedman Associates IR Agency of Record 3Health News:Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference 2Health News:Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 2Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 3Health News:SGX Pharmaceuticals BCR-ABL Program to be Presented at the American Society of Hematology 49th Annual Meeting and Exposition 4
(Date:7/25/2014)... July 25, 2014  CVS Caremark Corporation (NYSE: ... on Tuesday, August 5, 2014, at 8:30 a.m. (EDT) ... 2014 financial results. An audio webcast of ... Investor Relations portion of the CVS Caremark website for ... http://info.cvscaremark.com/investors . This webcast will be archived and available ...
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... , July 25, 2014  Acsis Inc., ... protection and serialization solutions, has recently posted an ... that addresses current and future needs for companies, ... the old supply chain model no longer work ... technology, including the growth of mobile technology, machine ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Acsis Addresses Questions on the Modern Supply Chain 2
... WIRE)--Jun 19, 2007 - Javelin,Pharmaceuticals (AMEX: JAV) ... morphine) successfully met its,primary clinical endpoint, the ... over 0-24 hours postoperatively. In this first ... moderate-to-severe pain,after elective orthopedic surgery were given ...
... --,Nuvelo, Inc. today announced the publication of the ... rNAPc2,To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) ... of Cardiology (JACC), demonstrating,that higher-dose (greater than or ... (rNAPc2) reduced the incidence,and duration of ischemia as ...
Cached Medicine Technology:Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 2Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 3Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial,Data 4Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 2Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 3Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology 4
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Direct has been selling replacement ... 1996, and we are extremely ... guarantee. Check out our catalog ... our discount light bulbs specials. ...
Medicine Products: